Background. Opsonophagocytic assays (OPAs) are an important tool for assessing vaccine-induced functional antibody responses. OPAs are complex assays composed of many biological components (eg serum, complement sources, bacteria, and human phagocytes) which contribute to assay variability and may result in titer drift if not carefully controlled. Rigorous development and validation coupled with routine monitoring of assay performance are required to ensure that high-quality OPA serological data are consistently generated throughout the lifetime of existing and next-generation pneumococcal vaccines.
Methods. OPA specificity was demonstrated by competing functional antibody activity with pneumococcal polysaccharides. Assay qualification/validation assessed accuracy, precision, and sample linearity. Assay performance over time was assessed through the implementation of quality control serum data tracking systems and longterm serum proficiency panels that are routinely tested during assay performance. Human quality control sera are included on each assay plate to ensure that each plate meets pre-specified acceptance criteria. Proficiency serum panels are comprised of individual human serum samples derived from subjects immunized with pneumococcal vaccines and are used to monitor performance across a range of serological titers and over time.
Results. The OPAs were shown to be specific and reproducible. Monitoring of assay performance over time demonstrated that the assays are stable. For the 13 serotypes contained in 13vPnC reliable titers have been generated in over a decade of testing which is an essential prerequisite in the evaluation of next-generation pneumococcal conjugate vaccines such as 20vPnC, whose licensure depends on demonstration of non-inferiority to 13vPnC.
Conclusion.
Maintenance and careful monitoring of high-quality assays to measure functional antibody responses, such as OPAs, is critical for the delivery of reliable serological data to support the advancement of pneumococcal vaccine programs. Pneumococcal OPAs must be rigorously maintained to ensure continuity of serological data over time and inform licensure decisions of next-generation vaccines as well as postmarketing and seroepidemiology studies.
Disclosures. All authors: No reported disclosures. Early diagnosis and treatment of tick-borne diseases (TBDs) is critical for mitigating their adverse health outcomes, but the differential diagnosis of TBDs is challenging because many symptoms are nonspecific and commonly used diagnostic assays have significant shortcomings. Furthermore, although the local incidence of TBDs is recognized as an important factor in diagnosis, tools to help clinicians formally consider surveillance data in their decision-making are not available. To address these gaps, Gryphon Scientific developed a differential diagnosis application (app) for TBDs that calculates a patient's likelihood of infection with specific TBDs based on their symptoms, risk factors, and state of suspected tick exposure. Methods. A differential diagnosis model for TBDs was developed using data on: (1) TBD symptom and risk factor prevalence in TBD patient populations, collected from clinical studies; and (2) human TBD incidence data from notifiable disease surveillance systems and tick infection prevalence data from reports and public databases, which were combined to develop an environmental risk measure. These data were used to build a Bayesian Belief Network (BBN) model that predicts TBD infection probabilities based on a patient's symptoms, risk factors, and state of suspected tick exposure. Performance of the model was validated using case studies from the biomedical literature. The model was incorporated into an app developed using R-shiny, called TBD-DDx (Figures 1 and 3) .
Development of a Novel Application for Differential Diagnosis of Tickborne Diseases
Results. A pilot application was developed that includes 10 states (AR, CT, MA, ME, MN, MO, NH, RI, VT, and WI) and the 11 TBDs endemic to those states. The differential diagnosis model identified the patient's true disease as the top-predicted disease in 56% of cases and within the top three predicted TBD in 84% of cases. The inclusion of incidence factors in the model improved performance (Figure 4) .
Conclusion. These results demonstrate that the TBD-DDx app is a promising tool for informing clinical diagnoses of TBDs to guide selection of diagnostic testing and treatment. This study represents the first use of a BBN modeling approach that incorporates an environmental risk measure and could be adapted for differential diagnosis of other diseases with environmental or other exposure risks. Background. Procalcitonin (PCT) has emerged as a biomarker distinguishing bacterial from non-bacterial infections with FDA approval for acute respiratory infections and sepsis. Studies show that PCT use can reduce patient harm while decreasing antibiotic usage. Our objective was to evaluate PCT use at our hospital and assess the impact of a comprehensive education intervention.
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Methods. In-house PCT testing was implemented at our institution April 2018 along with a rigorous education campaign. Interventions consisted of face-to-face didactics with 5 provider groups, distribution of evidence-based interpretation algorithms, development of EMR prompts to guide appropriate ordering, and creation of syndrome-specific interpretation displayed with PCT results. Retrospective analysis comparing pre-intervention (December 2017) to post-intervention (October 2018) was performed evaluating ordering habits and impact of PCT result on antibiotic management. Statistical analysis was performed using STATA 14.2.
Results. 218 PCT orders from 170 patients and 263 PCT orders from 170 patients were included in the pre-and post-intervention periods, respectively. All provider groups who received face-to-face education changed PCT ordering habits. Orders placed in ED and ICU locations increased (P < 0.01 and P = 0.01, respectively) while orders from floor locations decreased (P < 0.01). Serial PCT orders increased (20% vs. 33%; P < 0.01). PCT orders for FDA-approved indications improved (71% vs. 90%; P < 0.01) and following intervention, services who received in-person didactics were more likely to order PCT for FDA-approved indications than untrained groups (93% vs. 80%; P < 0.01). Clinicians were less likely to adjust therapy when PCT was low than when elevated in both periods (55% vs. 72%; P = 0.01; 61% vs. 77%; P = 0.01, respectively). Providers appropriately altered or continued therapy at similar rates during both periods (64% vs. 70%; P = 0.2).
Conclusion. Providing comprehensive PCT education significantly impacted PCT ordering habits. Testing improved to comply with FDA-approved indications, specifically in providers who received face-to-face education. Appropriate alteration of therapy based on PCT results were similar between groups suggesting repeat education is needed to avoid confirmation bias.
Disclosures. All authors: No reported disclosures. Background. Sepsis frequently leads to acute kidney injury. In severe cases, patients may require continuous renal replacement therapy (CRRT) which involves placement of a dialysis catheter and an extracorporeal blood filtration circuit. CRRT is commonly considered to "mask" fever, though this phenomenon has not been investigated.
The Effect of Continuous Renal Replacement Therapy on Body
Methods. We queried an institutional database of all patients on CRRT from 2007 to 2015 for inpatient temperature data and antibiotic administration records. Receipts of piperacillin-tazobactam, a carbapenem, or a third or fourth-generation cephalosporin, indicating a serious infection, were considered intervention arm. We analyzed temperatures recorded in the intensive care unit before, during, and after CRRT. Patients were divided into groups that did not receive antibiotics as well as those who did. Temperature data were Winsorized to correct for outliers. We also performed descriptive statistics for each group.
Results. There were 237,988 temperature readings for 1,568 ICU patients on CRRT. 1,153 patients received broad-spectrum antibiotics in ICU. In patients who received antibiotics in ICU and were presumed to have an infection, the mean temperature was 37.2°C prior to initiation of CRRT, 36.8°C while on CRRT, and 37.2°C following discontinuation of CRRT. In the 415 patients who did not receive IV antibiotics, the mean temperature was 36.9°C prior to initiation of CRRT, 36.6°C while on CRRT, and 37.0°C following discontinuation of CRRT. During each of the periods before, during, and after CRRT, patients who received antibiotics had significantly higher temperatures than those who did not (P < 0.001). Patients receiving antibiotics were generally younger (mean 60 years vs. 64 years, P < 0.001), had longer ICU stays (mean 29 days vs. 12 days, P < 0.001) and spent more time being ventilated (mean 23 days vs. 7 days, P < 0.001). The mean SOFA score on day one was similar (mean 11.1 in the antibiotic group and 10.5 in the other group).
Conclusion. This investigation suggests that patients have slightly lower temperatures while on CRRT, by on average less than half a degree. A similar effect is seen in both patients with infections as well as those without. Further work will be needed to determine what constitutes a true febrile response in this population.
Disclosures. Background. Nontuberculous mycobacteria (NTM), particularly Mycobacterium avium complex and Mycobacterium abscessus complex, cause significant morbidity and mortality in patients with impaired host immunity or pre-existing structural lung conditions. NTM infections are increasing at an alarming rate worldwide and there is a dearth of progress in regard to the development of efficacious and tolerable drugs to treat such infections. Traditional drug discovery screens do not account for the diverse physiological conditions, microenvironments, and compartments that the bacilli encounter during human infection. In order to help populate the NTM drug pipeline, and explore the disconnect between in vitro activity, in vivo activity, and clinical outcomes, we are developing a high throughput in vitro assay platform that will more closely model the unique infection-relevant conditions encountered by NTM.
Methods. We are developing and validating a suite of in vitro assays that screen compounds for activity against extracellular planktonic bacteria, extracellular bacteria within biofilms, intracellular bacteria, and nutrient-starved non-replicating bacteria.
Results. We are using both the smooth and rough morphotypes of M. abscessus and M. avium. We have validated high throughput assays to pharmaceutical standards for replicating and non-replicating M. abscessus. We have also tested a panel of 18 known anti-mycobacterial compounds. Assay development is currently underway to test compounds for activity against NTM in biofilm and inside macrophages as well.
Conclusion. To enhance hit identification for scaffolds to use as starting points for NTM drug development, focused libraries of compounds that have undergone significant preclinical profiling and/or compounds with known activity against M. tuberculosis (TB) will be screened. Such a "piggyback" approach usurps advances made in TB drug development and leverages them for NTM drug discovery. This will help expedite novel drug development, reduce attrition rate, and offer a shorter route to clinical use as it exploits the prior investment in medicinal chemistry, pharmacology, and toxicology.
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